Category

• Pipeline3

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• Clinical Trials3
• Retinitis Pigmentosa2
• FDA1
• Usher Syndrome1
• Cataract1
• Ocular Implants1
• Retina1

• Organizations: Nacuity Pharmaceuticals✕

Clear all

Pipeline

FDA grants Nacuity Pharmaceuticals Fast Track designation for RP tablets

Preclinical data showed NPI-001 (N-acetylcysteine amide) preserved photoreceptor cells and functionality; therapy is in clinical trials for RP associated with Usher syndrome.

Pipeline

Nacuity moves forward with trial of intravitreal implant for cataract progression delay

First cohort in proof-of-concept study is enrolling patients undergoing vitrectomy.

Pipeline

Target enrollment achieved in trial for RP associated with Usher syndrome

The phase 1/2 study is assessing NPI-001, developed to block oxidative stress associated with RP and other blinding eye diseases.